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repeated cycles of sublethal irradiation
BI Lord', E Marshall2, LB Woolford' and MG Hunter3
'CRC Department ofExperimental Haematology, Paterson Institutefor Cancer Research, and 2Department ofMedical Oncology,
Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK; 3British Biotech Pharmaceuticals Ltd, Watlington Road,
Oxford OX4 SLY, UK.
Summary Macrophage inflammatory protein-la (MIP-la) is an inhibitor of stem cell proliferation affording
protection against damage from agents that express their cytotoxicity specifically in the DNA synthesis phase
of the cell cycle. Its ability also to modify the self-renewal capacity of the regenerating cells is now shown to
improve and maintain haemopoietic recovery following therapy (sublethal irradiation) whose cytotoxic damage
is not limited solely to the DNA-S phase of this cycle. Such non-cell cycle-active cytotoxic agents are used
clinically in repeated treatment regimens, which are often limited or terminated because of accumulating
haemopoietic damage. BB-10010, a non-aggregating variant of MIP-la, was administered as a continuous dose
(1600 ,ug kg-l 24 h-') via a subcutaneously implanted pump over a period of 7 days. A dose of 4.5Gy total-
body y-rays was given 3-4 h after implantation. Day 8 and 12 spleen colony-forming units (CFU-S) were
assayed on days 1, 7 and 14 after irradiation. This cycle of treatment was repeated four times (total 56 days),
and on day 14 of the last two cycles the marrow-repopulating ability (MRA) was also measured. In the control
bone marrow (no BB-10010) CFU-S fell to < 1% of normal within 1 day of irradiation and recovered to 40%
at 14 days. Repeated treatments increased the level of damage, and after four cycles CFU-S recovered to only
10% of normal. BB-10010 afforded little benefit in the first treatment cycle, but by the end of the fourth cycle
CFU-S still recovered to 35% of normal. MRA was reduced to 7% of normal by the irradiation protocol -
about half that maintained by BB-10010 protection. We conclude that BB-10010 (MIP-la) reduces the degree
of accumulated haemopoietic stem cell damage following repeated non-cell cycle-specific cytotoxic insults - a
principle which should be valuable in repeated clinical cytotoxic therapy regimens.
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Macrophage inflammatory protein-lbx (MIP-loa) has been
recognised as a haemopoietic stem cell proliferation inhibitor
by its capactiy to protect multipotent progenitor cells from
cytotoxic agents, which are effective against cells specifically
in DNA synthesis, both in vitro and in vivo (Lord et al., 1976;
1992 Wright and Lord, 1977; Graham et al., 1990; Clements
et al., 1992; Dunlop et al., 1992; Cooper et al., 1994). In one
series of experiments in which MIP-lax was given in vivo to
protect haemopoietic spleen colony-forming units (CFU-S)
(Till and McCulloch, 1962) from the effects of hydroxyurea
(HU), the subsequent recovery rate of the (partially)
protected population appeared to be higher than in the
control (HU-treated) population (Lord et al., 1992). This was
complementary to an earlier observation that the partially
purified inhibitor enhanced the generation of haemopoietic
cells in long-term bone marrow cultures (Lord et al., 1987).
Furthermore, it led to the suggestion that, in addition to its
capacity to block the progression of progenitor cells into
DNA synthesis, MIP-la had effects also on the self-renewal
and differentiation capacity of the surviving multipotent
progenitor cell population (Lord et al., 1992). This enhanced
rate of recovery of the CFU-S population has recently been
confirmed and direct measurements showed the self-renewal
capacity of the CFU-S population surviving HU treatment to
be enhanced by MIP-la given in vivo (Lord, 1995).
These observations together suggested that the clinical
value of MIP-la need not be limited to protection of
haemopoietic stem cells from cytotoxic agents which
specifically damage the DNA synthesis phase of the cell
cycle. CFU-S populations depleted by non-cell cycle-specific
treatments, but exposed to MIP-la, might emerge with a
higher self-renewal capacity, thus restocking the stem cell
compartments more efficiently and making them less
susceptible to the accumulating damage incurred by the
repeated treatment cycles commonly used in chemotherapeu-
tic regimens.
Repeated sublethal doses of irradiation result in a long-
term accumulation of damage such that recovery of the
CFU-S population is successively more impaired, i.e. the
plateau level of CFU-S recovery is lower with each successive
cycle of radiation (Hendry and Lajtha, 1972). Such damage is
equivalent to that frequently encountered in chemotherapy
programmes where successive cycles of treatment may have
to be delayed or terminated after four or five cycles because
of deteriorating marrow recovery. We have now used this
radiation model as a form of repeated courses of cytotoxic
treatments and demonstrate that a non-aggregating variant of
MIP-la, BB-10010, introduced before the radiation treatment
and extending for several days thereafter, results in recovery
that can better withstand subsequent cycles of cytotoxic
treatment.
Materials and methods
Mice
Male B6D2F1 (C57BlY x DBA2&) mice, aged 10 weeks at
the start of experiments, were used throughout and all
procedures were carried out under licence from the Home
Office, Animals (Scientific Procedures) Act, 1986.
BB-10010/MIP-la
BB-10010 was kindly supplied by British Biotech Pharmaceu-
ticals Ltd. (Oxford, UK) as a non-aggregating, genetically
engineered variant ofhuman MIP-lao (or LD78). It was shown
to have greatly increased solubility compared with human
MIP-la and was equipotent with MIP-lo in receptor binding,
calcium mobilisation, inhibition of colony formation and
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thymidine suicide assays (Hunter et al., 1995). It is prepared to
standards required for clinical use with purity better than 98%
and the protein contains less than 2 endotoxin units mg-' as
determined by the limulus amoebocyte lysate assay (Hunter et
al., 1995). BB-10010 was administered by mini-osmotic pumps
(Alzet 2001, CA, USA) implanted subcutaneously on the backs
of mice and delivering a uniform BB-10010 dose of 40 ,g per
24 h period for 7 days.
CFU-S assays
Haemopoietic spleen colony-forming units (CFU-S) were
assayed as previously described (Lord, 1993). Briefly, mice
(groups of 20) were irradiated (whole body) with 15.25 Gy
'Co y-rays (0.95 Gy h-1). They were then injected intrave-
nously with 0.2 ml of a freshly prepared suspension of bone
marrow cells from mice treated as described above. Eight days
(ten mice) and 12 days (ten mice) later the recipient mice were
killed. Their spleens were excised, fixed and the macroscopic
colonies counted using a dissecting microscope.
Marrow repopulating ability assays (MRA)
The MRA was measured as the generation of 12 days CFU-S
during 13 days' growth in the marrow by an extension of the
CFU-S assay (see Lord, 1993 for details), on day 14 of the
third and fourth treatment cycles. An extra five irradiated
(primary) recipients were injected with the bone marrow
suspension. After 13 days their femora were removed. Bone
marrow suspensions were made and assayed for CFU-S12 in
secondary groups of ten irradiated recipients as described
above. MRA was calculated as:
c xp x q per femur c x p x q x 105 per 105 cells,
N
where N=number of donor marrow cells per femur;
c=number of CFU-S12 colonies per secondary spleen; 1/q=
fraction of donor marrow cells injected to primary recipient;
and I/p =fraction of primary recipient marrow injected in
secondary recipient.
Three secondary assays were carried out for each primary
recipient bone marrow pool for which p= 10, 20 and 40. In
these experiments q=50 or 100.
Protocols
(1) Groups of three mice were implanted subcutaneously
with mini-osmotic pumps delivering BB-10010 (40 ug
per 24 h period for 7 days) or its vehicle, phosphate-
buffered saline (PBS). Three to four hours later they
were exposed (whole body) to 4.5 Gy y-rays from a
caesium-137 source (dose rate 2.5 Gy min-') and after 7
days the spent pumps were removed. Groups of mice
were killed at 1, 7 and 14 days after irradiation and their
femora and spleens removed. Cell suspensions were
made in Fischer's medium from the bone marrow and
spleen (Lord 1993 for details), counted and assayed for
day 8 (CFU-S8) and day 12 (CFU-S2) colony-forming
units. The cellular concentrations of the inoculation
suspensions were adjusted so that 0.2 ml injected
Table I Fractions of one femur or spleen injected for CFU-S assay
Assay daya BM Spleen MIP-BM MIP-spleen
1 1/3 1/6 1/3 1/6
7 1/10 1/10 1/40 1/40
14 1/100 1/100 1/100 1/100
aRepeated for each 14 day cycle of treatment and assay.
contained the fraction of a femur or spleen indicated
in Table I. These figures should be considered merely as
a guide. Throughout the course of the four experiments
reported below, they were continuously refined to
optimise the average spleen colony counts, where
possible, at about 10.
This 2 week cycle of pump, irradiation and assays was
repeated three more times in a total observation period of 56
days. On days 42 and 56 (ends of the third and fourth
treatment cycles) marrow cells were additionally assayed for
MRA.
(2) A separate series of experiments was conducted to
explore whether BB-10010 has any direct radioprotective
capacity or whether its presence is important only during
the recovery phase. Observations were limited in these
experiments to two 14 day cycles of 4.5 Gy whole body
'37Cs-y irradiation and recovery. Groups of three mice
were implanted with minipumps dispensing BB-10010
(or PBS) from day 0 (3-4 h before irradiation) to 7,
from 1 day after irradiation to 8 days or from 7 days
after irradiation to 14 days in each treatment cycle. They
were killed on day 14 of the second treatment cycle and
bone marrow CFU-S assays carried out as before.
Results
The repeated irradiation treatment regimen was conduct in
four separate experiments and the overall results are shown
in Table II and Figures 1 and 3. For each cycle of
treatment, the cellularity of the control bone marrows fell to
about 20-30% of normal within 24 h but recovered to near
normal levels within 14 days (Table II). A similar pattern of
loss and recovery was evident in the BB-10010-treated mice
and at the end of each of the four treatment cycles, the
average marrow cellularity was 29% higher than in the
controls (P=0.002). In the first treatment cycle, bone
marrow CFU-S were reduced to less than 1% of their
normal levels and in 14 days, CFU-S8 and CFU-S12
recovered to 40% and 20% respectively (Figure 1). BB-
10010 induced a small, but non-significant increase in the
recovery rate of both CFU-S8 and CFU-S2.
Repeated cycles of irradiation increased the damage to
CFU-S in the untreated marrows. One day after irradiation,
CFU-S survival levels were successively lower (Figures 1 and
2) as were the 14 day recovery levels (Figures 1 and 3),
CFU-S8 reaching only 10% and CFU-S12 6% of their
Table II Femoral bone marrow cellularity in mice subjected to
repeated cycles of sublethal irradiation, with or without BB-10010
Femur (xle6)
Time (days) Femur (x la ) with BB-JOOJO
0 20 20
1 5.1+0.5 4.2+0.4
7 15.8+2.0 20.0+2.5
14 17.0+1.7 18.1+2.3
15 7.2+1.6 8.2+5.6
21 23.2+3.1 20.0+3.4
28 16.5+2.1 23.3+2.6
29 4.0+1.4 4.1+0.7
35 13.4+2.7 24.5+4.1
42 16.0+2.4 18.9+1.6
43 4.1+0.3 5.0+0.4
49 20.8+3.5 14.0+2.8
56 14.7+2.5 22.3+3.1
Mice were exposed to 4.5 Gy y-rays on day 0 and at 14 day intervals
thereafter. Data are for three to four experiments+s.e. Data for day 0
are standardised norms for these mice and are presented simply as
approximate reference points.Radiprotection by MIP-la
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Figure 1 Eight and twelve day CFU-S in the bone marrow of mice subjected to repeated 14 day cycles of total body, 4.5Gy y
irradiation. The shaded bars on the abscissae indicate the presence of a mini-osmotic pump dispensing BB-10010 (0) or PBS (0).
Data are means from 3-4 experiments+s.e. Data for day 0 are standardised norms for these mice and are presented simply as
reference points.
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Figure 2 Detail of the 1 day after irradiation nadirs in bone marrow CFU-S following sequential 2-weekly doses of 4.5 Gy y-rays
(whole body). (0) Irradiation +PBS; (0) irradiation+ BB-10010.
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Figure 3 Detail of the 14 day after irradiation recovery values for bone marrow CFU-S following sequential 2-weekly doses of
4.5Gy y-rays (whole body). (0) Irradiation +PBS; (0) irradiation +BB-10010.
starting levels after the fourth cycle of treatment. Intrinsic
errors in measuring the very low CFU-S numbers 1 day
after irradiation are unavoidably high. Figure 2, however,
indicates that BB-10010 had little effect in the first cycle, but
after the fourth cycle of treatment, about twice as many
CFU-S survived (Figures 1 and 2 for CFU-S8 and CFU-S12,
P<0.01 in the fourth cycle). The degree of recovery was
maintained with each successive treatment cycle (Figures 1
and 3, P<0.001 over cycles 2-4 for CFU-S8 and CFU-S12)
and at the end of the fourth treatment cycle both CFU-S8
and CFU-Sl2 were about 35% of normal levels in the BB-
10010-treated mice compared with less than 10% without
BB-10010.
At the end of each treatment cycle, splenic CFU-S8 had
recovered equally well with or without BB-10010 but for the
most part, maximum recovery was achieved earlier (by 7
days) with BB-10010 (Figure 4). This was true also for CFU-
S12 which in the non-protected mice were still on the recovery
curve at 14 days in the second, third and fourth cycles.
Marrow repopulating ability is normally recorded for
these mice at about 105 per femur or 500 per 105 marrow cells
(Lord and Woolford, 1993). Thirteen day recovery marrow in
the third and fourth cycles of sublethal irradiation yielded an
MRA of only 6500-7300 per femur at concentrations less
than 10% of normal (Table III). Treatment with BB-10010
yielded an MRA of 26 600 (P<0.001) after the third cycle
and 11 206 (P<0.02) after the fourth cycle of irradiation
(Table III). The corresponding increase in cellular concentra-
tion of MRA cells of 1.3-3 times reflected the increase
previously reported in self-renewal capacity of the stem cell
populations following MIP-la treatment (Lord, 1995).
Over two cycles of irradiation treatment, CFU-S in mice
receiving PBS alone recovered to 730 per femur (Table IV).
Pumps delivering BB-10010 during and after irradiation
increased this to 1270 (P=0.01). Less advantage was
obtained when BB-10010 dosing was delayed by 1 day (960
CFU-S per femur, NS), and none at all when dosing in the
second half of each radiation cycle.
Discussion
It is a common feature associated with repeated cycles of
cytotoxic therapies that accumulating damage to the
haemopoietic tissue often results in delays to the administra-
tion of the later treatments; indeed possibly to the
curtailment of further cycles. Experimentally, it is known
that repeated doses of sublethal irradiation also result in
accumulating damage to the spleen colony-forming units
(Hendry et al., 1974). We chose, therefore, to use irradiation
as a convenient model to test the potential of BB-10010 to
maintain recovery of the stem cell populations. The
4 x 4.5 Gy irradiation model described by Hendry et al.
(1974) was adopted, although the repeat interval was
shortened to 14 days. This was to ensure suboptimally
recovered haemopoietic tissue and, therefore, avoid any
likelihood of masking beneficial effects of BB-10010. The
progressively lower 1 day survivals and 14 day recovery peaks
with increasing cycle number confirm that haemopoietic
damage was accumulated through the experiment (Figures 2
and 3). In addition, and in spite of their somewhat greater
radioresistance (Meijne et al., 1991; Ploemacher et al., 1992),
the marrow repopulating cells also demonstrated significant
accrued damage (Table II).
It has previously been shown that protection from
hydroxyurea damage, using MIP-la, results in a more rapid
recovery of the multipotent progenitor populations that are
relatively enriched in the better self-renewing cells (Lord,
1995) - probably the cells with MRA. This result
complemented those of Verfaille et al. (1994) who demon-
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Figure 4 Eight and twelve day CFU-S in the spleens ofmice subjected to repeated 14 day cycles of total body, 4.5Gy y-irradiation.
The shaded bars on the abscissae indicate the presence of a mini-osmotic pump dispensing BB-10010 (0) or PBS (0). Data are
means from 3 -4 experiments+ s.e. Data for day 0 are standardised norms for these mice and are presented simply as reference
points.
Table III MRA of progenitor cells in bone marrow of mice
subjected to repeated cycles of sublethal irradiation, with or without
BB-10010
CFU-S12 MRA Per
Cells per primary donor
Bone marrow donorfemurfemur femur
Day donor ( x lO) (=c x p) (=c x p x q)
0 Normal 20 - 105
42 Irradiated 13.5 65.3+3.5 6533+352
(n =3) Irradiated + 17.75 266+ 14 26600+ 1386
BB-10010
56 Irradiated 15.75+0.05 61.0+4.6 7266+688
(n=9) Irradiated+ 22.0+3.2 114+19 11206+1313
BB-10010
Three secondary assays were carried out for each primary recipient
bone marrow pool (taken at 13 days after transplant) for which p = 10,
20 and 40. In these experiments q = 50 or 100. c, p and q are defined in
the text. aData for normal mice are taken from Lord and Woolford
(1993). Current data are mean values+s.e.
strated that the equivalent in vitro long-term culture-initiating
cells were maintained better in cultures treated with MIP-lcI
(in combination with IL-3). This modulation in favour of
self-renewal potential effectively reduces differentiation
potential. It does not necessarily adversely affect the
production of differentiated cells, however. Indeed, the
increased reserves of 'stem' cells generated by increased self-
renewal, can provide a pool that is more than adequate to
compensate the reduced differentiation rate. We reasoned,
therefore, that recovery from sublethal doses of irradiation
could be similarly enhanced by the presence of MIP-lac,
during and after the period of irradiation.
The results presented here indicate that this rationale was
sound. BB-10010 gave little, if any, protection from the first
dose of irradiation but the better recovery characteristics,
Table IV Recovery of bone marrow CFU-S following radiation:
dosing with BB-10010 at vaious times before or after radiation
BB-JOOJO treatment CFU-S perfemura
4.5 Gy y-rays only 730+94
Days 0-7 1270+ 127
Days 1 -8 960+69
Days 7- 14 690+64
aData for CFU-S8 andCFU-S12 combined. Results are for mean of
three experiments+s.e.
particularly in respect of the highly enriched MRA, ensured
that the second and subsequent irradiations caused progres-
sively less initial damage (Figure 2) and that the recovery
patterns did not significantly deteriorate (Figure 3).
In these experiments, our primary aim was to assess the
ability of BB-10010 to support a better quality haemopoietic
progenitor cell component in the bone marrow and spleen.
The design of the experiments, therefore, was such that
simultaneous recording ofperipheral blood cell levels was not
practical. Preliminary experiments (unpublished data) with
cyclophosphamide and 5-fluorouracil (5-FU) suggest that
neutrophil production is promoted by 1-2 days, supporting
the observations of Dunlop et al. (1992). These experiments
demonstrated a fuller and earlier recovery of the progenitor
populations with full restoration of the haemopoietic,
nucleated cell populations and consistent with conditions
for earlier recovery of the mature cell products. The very
early recovery of the splenic CFU-S population (Figure 4)
would be expected to contribute to such a process. However,
the role of the spleen is not clear. It has to be recognised that,
relative to total haemopoiesis, the splenic contribution is
small and, in a comparable human protocol, would probably
play no part.
In these experiments, BB-10010 was supplied continuously
for 7 days of each cycle. At this stage, we have no evidenceRadloprotection by MIP-lx
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that this length of time is necessary, nor even that the MIP-
la remains active under these conditions for the whole 7
days. The timing and administration protocols, therefore,
remain the subject of further investigation.
While it is clear that this type of protocol is a practical
scenario, the mechanisms by which MIP-la is promoting
recovery are not clear. The demonstration that MIP-lcx
contributes to a better maintenance ofprimitive haemopoietic
stem cells (Verfaillie et al., 1994), that a CFU-S population
regenerating after exposure to MIP-la has a higher self-
renewal capacity (Lord, 1995) and supported by a recent
observation that recovery is enhanced following cyclophos-
phamide (a non-S-phase-specific cytotoxic agent) treatment
(Parker et al., 1995), all suggest that recovery kinetics are
improved by MIP-la. It is not clear whether MIP-la (BB-
10010 in this instance) has any direct radioprotective effect.
Initial depopulation ofCFU-S (1 day nadir, cycle 1, Figure 2)
suggests not. However, those recovery characteristics were
clearly improved by the presence of BB-10010 at the time of
irradiation (Table IV). Delay ofexposure to BB-10010 until 1
day after irradiation ameliorated the recovery significantly
and when administered during the later stages of recovery, it
gave no beneficial advantage (Table IV).
In summary, we conclude that the cumulative effects of
non-cycle-specific cytotoxic therapies on normal haemopoiesis
can be ameliorated by the administration of BB-10010/MIP-
la during, and in the aftermath of, such treatments. These
experiments should, therefore, provide a base for protection
experiments and treatments with other clinically appropriate
cyclical therapies using cytotoxic alkylating agents. Ulti-
mately, they should be directly transferable to appropriate
clinical scenarios in the treatment of cancer.
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